Limits...
Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer.

Shin NR, Lee YY, Kim SH, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG - Obstet Gynecol Sci (2014)

Bottom Line: Median pretreatment hemoglobin (Hb) level was 12.8 g/dL (4.0-16.9) in all patients.Ninety-ninth out of 805 patients had pretreatment anemia (12.3%).In conclusion, we found that the negative association between pretreatment Hb level and tumor size and the impact of anemia before treatment on disease free survival adjusted for other factors including clinical stage and pathological findings in early stage cervical cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ABSTRACT

Objective: The purpose of this study is to investigate the prognostic role of pretreatment anemia in patients with early cervical cancer who underwent radical hysterectomy.

Methods: In this study, we retrospectively enrolled patients with early cervical cancer (International Federation of Obstetrics and Gynecology stage IB to IIA) who were treated at Samsung Medical Center, Seoul, Korea, from 1996 to 2007.

Results: We retrospectively enrolled 805 patients. Median pretreatment hemoglobin (Hb) level was 12.8 g/dL (4.0-16.9) in all patients. Ninety-ninth out of 805 patients had pretreatment anemia (12.3%). Pretreatment anemia was significantly associated with large tumor size, advanced clinical stage, and parametrial invasion. In multivariate analysis, higher pretreatment Hb entailed better prognostic significance in disease free survival (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.078-0.99) but not in overall survival (HR, 0.94; 95% CI, 0.80-1.10).

Conclusion: In conclusion, we found that the negative association between pretreatment Hb level and tumor size and the impact of anemia before treatment on disease free survival adjusted for other factors including clinical stage and pathological findings in early stage cervical cancer.

No MeSH data available.


Related in: MedlinePlus

The association between pretreatment hemoglobin (Hb) level and International Federation of Obstetrics and Gynecology (FIGO) clinical stage (A) and tumor size (B).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3924748&req=5

Figure 2: The association between pretreatment hemoglobin (Hb) level and International Federation of Obstetrics and Gynecology (FIGO) clinical stage (A) and tumor size (B).

Mentions: When we divided the patients into two groups according to whether the patients had pretreatment anemia or not, there was no statistical significant difference between groups but trends were shown that the patients with pretreatment anemia may have worse survival outcomes when compared with the patients without anemia (Fig. 1). Then we compared the association between pretreatment anemia and clinico-pathological findings which have been known as risk factors for recurrence. First, patients with IB2 had lower pretreatment Hb level compared with the patients with IB1, which was statistically significant (P=0.016), and negative correlation was observed between tumor size and pretreatment Hb level with statistical significance (R2=-0.089, P=0.011) as shown in Fig. 2. Second, among the high risk factors for recurrence, microscopic parametrial invasion was significantly associated with pretreatment anemia (P=0.002) (Table 2). However, pretreatment Hb level was not associated with lymphatic invasion of tumor cells including lympho-vascular space invasion or LN metastasis as well as histologic subtypes and vaginal resection margin with tumor.


Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer.

Shin NR, Lee YY, Kim SH, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG - Obstet Gynecol Sci (2014)

The association between pretreatment hemoglobin (Hb) level and International Federation of Obstetrics and Gynecology (FIGO) clinical stage (A) and tumor size (B).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3924748&req=5

Figure 2: The association between pretreatment hemoglobin (Hb) level and International Federation of Obstetrics and Gynecology (FIGO) clinical stage (A) and tumor size (B).
Mentions: When we divided the patients into two groups according to whether the patients had pretreatment anemia or not, there was no statistical significant difference between groups but trends were shown that the patients with pretreatment anemia may have worse survival outcomes when compared with the patients without anemia (Fig. 1). Then we compared the association between pretreatment anemia and clinico-pathological findings which have been known as risk factors for recurrence. First, patients with IB2 had lower pretreatment Hb level compared with the patients with IB1, which was statistically significant (P=0.016), and negative correlation was observed between tumor size and pretreatment Hb level with statistical significance (R2=-0.089, P=0.011) as shown in Fig. 2. Second, among the high risk factors for recurrence, microscopic parametrial invasion was significantly associated with pretreatment anemia (P=0.002) (Table 2). However, pretreatment Hb level was not associated with lymphatic invasion of tumor cells including lympho-vascular space invasion or LN metastasis as well as histologic subtypes and vaginal resection margin with tumor.

Bottom Line: Median pretreatment hemoglobin (Hb) level was 12.8 g/dL (4.0-16.9) in all patients.Ninety-ninth out of 805 patients had pretreatment anemia (12.3%).In conclusion, we found that the negative association between pretreatment Hb level and tumor size and the impact of anemia before treatment on disease free survival adjusted for other factors including clinical stage and pathological findings in early stage cervical cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ABSTRACT

Objective: The purpose of this study is to investigate the prognostic role of pretreatment anemia in patients with early cervical cancer who underwent radical hysterectomy.

Methods: In this study, we retrospectively enrolled patients with early cervical cancer (International Federation of Obstetrics and Gynecology stage IB to IIA) who were treated at Samsung Medical Center, Seoul, Korea, from 1996 to 2007.

Results: We retrospectively enrolled 805 patients. Median pretreatment hemoglobin (Hb) level was 12.8 g/dL (4.0-16.9) in all patients. Ninety-ninth out of 805 patients had pretreatment anemia (12.3%). Pretreatment anemia was significantly associated with large tumor size, advanced clinical stage, and parametrial invasion. In multivariate analysis, higher pretreatment Hb entailed better prognostic significance in disease free survival (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.078-0.99) but not in overall survival (HR, 0.94; 95% CI, 0.80-1.10).

Conclusion: In conclusion, we found that the negative association between pretreatment Hb level and tumor size and the impact of anemia before treatment on disease free survival adjusted for other factors including clinical stage and pathological findings in early stage cervical cancer.

No MeSH data available.


Related in: MedlinePlus